Regeneron Pharmaceuticals, Inc. REGN

NAS: REGN | ISIN: US75886F1075   25/04/2024
890,68 USD (-1,75%)
(-1,75%)   25/04/2024
Grafiek Regeneron Pharmaceuticals, Inc. Grafiek Regeneron Pharmaceuticals, Inc.
donderdag 2 mei 2024, 12:30
Kwartaalcijfers (1ste kwartaal)

Regeneron Pharmaceuticals, Inc. in het nieuws

13 maart 2024 · High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization · Persbericht

24 januari 2024 · Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards · Persbericht

8 januari 2024 · Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries · Persbericht

19 mei 2023 · High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023 · Persbericht

15 maart 2023 · Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease · Persbericht

24 januari 2023 · Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition · Persbericht

23 december 2022 · Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer · Persbericht

21 december 2022 · Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine · Persbericht

19 december 2022 · Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference · Persbericht

16 december 2022 · Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis · Persbericht

Profiel Regeneron Pharmaceuticals, Inc.

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.regeneron.com

Hoofdzetel: Tarrytown, New York vlag Verenigde Staten

CEO: Leonard Schleifer

Werknemers: 12.099

Aandelen Regeneron Pharmaceuticals, Inc.

Beurswaarde: 97,86 miljard USD

Effecten: 107,94 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 0,51

Mijn selecties